Mesoblast Limited
- MESO
- NASDAQ
- Biotechnology
- Cell Therapy
- Allogeneic Stem Cells
$12.02
Today −9.47%Quote Oct 19, 2026, 04:59 PM UTC
−10.69%over the last month
Max drawdown −16.6%From 1-month high −16.6%3 months −20.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Mesoblast
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
108
Market value
$15.59B
Quote Oct 19
Analyst target
$39.00
+224.4% from here
Resistance
$12.70
5.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MESOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free